Objective: To evaluate the efficacy of percutaneous ethanol injection (PEI) in the adjuvant treatment of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) by primary end point...Objective: To evaluate the efficacy of percutaneous ethanol injection (PEI) in the adjuvant treatment of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) by primary end points of time to progress (TTP). Methods: The study population consisted of 73 consecutive patients with inoperable HCC (China Classification System IIN liB). Among them, 22 patients were treated with TACE and PEI (experimental group), and the rest 51 were treated only with TACE (control group), and then the time to progress (TTP) and overall survival (OS) of these two groups were analyzed. Results: The median TTP was 10 months [95% confidence interval (CI), 7.9-12.1 months] in experimental group and 6 months (95% CI, 4.7-7.3 months) in control group. The 3-month,6-month, and 1-year Progression Free Survival (PFS) rates were respectively 77.3%, 63.6%, and 48.1% in experimental group, and 76.5%, 42.15%, and 24.8% in control group. The TTP of experimental group was significantly longer than that of control group (P 〈 0.05). The median survival period was 17 months [95% confidence interval (CI), 11-23 months] of experimental group and 12 months (95% CI, 10-14 months) of control group (P 〉 0.05). Conclusion: Compared with single TACE, the combination of TACE and PEI can obviously postpone disease progress and prolong survival of HCC patients.展开更多
Objective: The aim of this study was to evaluate the efficacy of transcatheter arterial chemoembolization (TACE) combined with a Chinese compound preparation of ganfule on advanced hepatocellular carcinoma (HCC)....Objective: The aim of this study was to evaluate the efficacy of transcatheter arterial chemoembolization (TACE) combined with a Chinese compound preparation of ganfule on advanced hepatocellular carcinoma (HCC). Methods: The study population consisted of 132 advanced HCC patients with Child-pugh NB. Tumor in all patients was involved with main trunk of portal vein and/or inferior vena cava, or local lymph node metastasis, or distant metastasis. TACE combined with ganfule were performed in 65 patients with advanced HCC (interventional treatment group), 67 patients were treated with traditional Chinese herbal drug alone (Chinese herb group). The prime end point was overall survival (OS), and prognostic factors were analyzed. Results: The median OS was 205 days [95% confidence interval (CI), 155-255 days] in interventional treatment group and 127 days (95% CI, 70-184 days) in Chinese herb group (P 〈 0.05). The 6-month, 1-year, and 2-year OS rates were 58.9%, 29.1%, 7.7% in interventional treatment group, and 33.3%, 12.3%, 1.8% in Chinese herb group, respectively. The portal vein thrombosis, ECOG performance status (PS) were independent prognostic factors for OS. Conclusion: Ttranscatheter arterial chemoembolization combined with a Chinese compound preparation of ganfule could greatly prolong the OS of advanced HCC patients. The portal vein thrombosis and ECOG PS were independent prognostic factors for OS.展开更多
文摘Objective: To evaluate the efficacy of percutaneous ethanol injection (PEI) in the adjuvant treatment of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) by primary end points of time to progress (TTP). Methods: The study population consisted of 73 consecutive patients with inoperable HCC (China Classification System IIN liB). Among them, 22 patients were treated with TACE and PEI (experimental group), and the rest 51 were treated only with TACE (control group), and then the time to progress (TTP) and overall survival (OS) of these two groups were analyzed. Results: The median TTP was 10 months [95% confidence interval (CI), 7.9-12.1 months] in experimental group and 6 months (95% CI, 4.7-7.3 months) in control group. The 3-month,6-month, and 1-year Progression Free Survival (PFS) rates were respectively 77.3%, 63.6%, and 48.1% in experimental group, and 76.5%, 42.15%, and 24.8% in control group. The TTP of experimental group was significantly longer than that of control group (P 〈 0.05). The median survival period was 17 months [95% confidence interval (CI), 11-23 months] of experimental group and 12 months (95% CI, 10-14 months) of control group (P 〉 0.05). Conclusion: Compared with single TACE, the combination of TACE and PEI can obviously postpone disease progress and prolong survival of HCC patients.
基金Supported by a grant from the Research Foundation of Fujian Provincial Health Department(No.2010-7)
文摘Objective: The aim of this study was to evaluate the efficacy of transcatheter arterial chemoembolization (TACE) combined with a Chinese compound preparation of ganfule on advanced hepatocellular carcinoma (HCC). Methods: The study population consisted of 132 advanced HCC patients with Child-pugh NB. Tumor in all patients was involved with main trunk of portal vein and/or inferior vena cava, or local lymph node metastasis, or distant metastasis. TACE combined with ganfule were performed in 65 patients with advanced HCC (interventional treatment group), 67 patients were treated with traditional Chinese herbal drug alone (Chinese herb group). The prime end point was overall survival (OS), and prognostic factors were analyzed. Results: The median OS was 205 days [95% confidence interval (CI), 155-255 days] in interventional treatment group and 127 days (95% CI, 70-184 days) in Chinese herb group (P 〈 0.05). The 6-month, 1-year, and 2-year OS rates were 58.9%, 29.1%, 7.7% in interventional treatment group, and 33.3%, 12.3%, 1.8% in Chinese herb group, respectively. The portal vein thrombosis, ECOG performance status (PS) were independent prognostic factors for OS. Conclusion: Ttranscatheter arterial chemoembolization combined with a Chinese compound preparation of ganfule could greatly prolong the OS of advanced HCC patients. The portal vein thrombosis and ECOG PS were independent prognostic factors for OS.